Bio Farma Continues to Control Integrated Transformation to Strengthen Business Foundation

Photo: Dok. Bio Farma

JAKARTA - PT Bio Farma (Persero) as the parent of the Pharmaceutical State-Owned Enterprise Holding continues to encourage transformation and continuous improvement across all subsidiaries and affiliates. The agenda is aimed at strengthening governance, improving operational discipline, optimizing assets and business capacity, and building a healthier and sustainable business competitiveness.

The transformation carried out in the Bio Farma Group environment is part of a comprehensive effort to ensure that each business entity has a stronger business foundation, is adaptive to the dynamics of the health industry, and is able to create added value for the country and all stakeholders.

One of the positive developments from the agenda can be seen in PT Indofarma (Persero) Tbk. Through efficiency measures, cost control, governance strengthening, and operational process optimization, Indofarma continues to make disciplined and measurable fundamental improvements.

Bio Farma President Director, Shadiq Akasya, in his statement, Sunday, June 28, conveyed that the transformation in all Bio Farma Group entities was not only oriented towards improving short-term performance, but was also directed at building a more solid business readiness in the long term.

"Bio Farma continues to encourage transformation and continuous improvement across all subsidiaries and affiliates to strengthen governance, operations, and business competitiveness. In Indofarma, the improvement steps have shown positive developments through efficiency, cost control, and operational optimization. This commitment is part of Bio Farma Group's efforts to support strengthening national health resilience as well as the contribution of the Indonesian health industry at the global level," said Shadiq Akasya.

According to Shadiq, strengthening governance and operational discipline is an important foundation for each entity in facing the increasingly complex industry challenges. Therefore, Bio Farma will continue to monitor the transformation steps through increased accountability, portfolio and asset optimization, strengthening production capabilities, and business development that is in line with market needs and national health priorities.

In the future, the Bio Farma Group will continue to strengthen inter-entity synergies to build a more integrated, resilient, and competitive health industry ecosystem. This step is expected to support the sustainability of the business of all group members while strengthening the contribution of the Indonesian pharmaceutical industry in maintaining national health resilience and expanding its role at the global level.